Key facts
- Apothékary’s last known valuation is $290.0M.
- It has raised $18.7M; the latest was Seed Round ($10.0M) in Nov 2024.
- Notable investors include Trousdale Ventures, Venrex Investment Management, The Venture Collective, Meach Cove Capital, Stella Capital (Chicago) — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Apothékary
- ·The full record, as it builds
Funding rounds
No funding rounds for Apothékary are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Apothékary
Operator of a herbal medicine company intended to offer clean, natural alternatives to over-the-counter drugs and supplements. The company offers herbal plant-based medicines that are natural, sustainable, and ethically sourced, enabling consumers to purchase natural alternatives to drugs at affordable prices.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Falls Church, VA, United States
- Founded
- 2018
- Employees
- 51
- Website
- apothekary.com/
- Ownership
- Privately Held (backing)
Apothékary doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Apothékary shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Apothékary in its N-PORT filings yet. We sweep new filings monthly.